IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by STF Management LP

STF Management LP lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,184 shares of the company’s stock after selling 168 shares during the quarter. STF Management LP’s holdings in IDEXX Laboratories were worth $598,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of IDXX. Crewe Advisors LLC acquired a new stake in IDEXX Laboratories during the first quarter worth approximately $26,000. Ridgewood Investments LLC purchased a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $27,000. Institutional & Family Asset Management LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. lifted its position in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IDXX shares. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. BTIG Research began coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. decreased their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Trading Up 0.2 %

NASDAQ:IDXX opened at $419.37 on Friday. The stock has a market capitalization of $34.34 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 3.63 and a beta of 1.36. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The stock has a fifty day moving average price of $462.53 and a two-hundred day moving average price of $481.11. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter last year, the business earned $2.53 earnings per share. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.